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The authors wish to clarify that this study was funded by ChiaNova Research, Inc., a company that was renamed (dissolved and assets transferred) to Salba Research & Development, Inc., in October 2002; the company has since been dissolved (in March 2006). The study agreement was signed in July 2001; the last installment of funds was received in June 2002.

The authors also wish to clarify that a patent application filed by V. Vuksan for the use of *Salvia hispanica L.* (Chia) for the treatment of cardiovascular disease, diabetes, and associated risk factors was pending at the time the manuscript was published. This patent has since been abandoned. This information was not disclosed when the manuscript was submitted and published because at that time the *Diabetes Care* conflict-of-interest policy did not specifically require the disclosure of such information.
